Phathom Pharmaceuticals (PHAT) Net Cash Flow (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Net Cash Flow data on file, last reported at $50.9 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at $50.9 million, up 159.96% year-over-year; the trailing twelve-month figure through Mar 2026 was -$31.4 million (up 71.42% YoY), and the FY2025 annual result was -$167.3 million, down 98.85% from the prior year.
• Net Cash Flow improved to $50.9 million in Q1 2026 per PHAT's latest filing, from -$5.2 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $167.7 million in Q4 2023 and troughed at -$84.9 million in Q1 2025.
• A 5-year average of -$5.6 million and a median of -$26.1 million in 2022 frame the typical range for Net Cash Flow.
• On a YoY basis, Net Cash Flow climbed as much as 556.3% in 2023 and fell as far as 211.16% in 2023.
• A 5-year view of Net Cash Flow shows it stood at -$41.5 million in 2022, then jumped by 504.61% to $167.7 million in 2023, then plunged by 122.31% to -$37.4 million in 2024, then soared by 86.14% to -$5.2 million in 2025, then surged by 1082.3% to $50.9 million in 2026.
• Business Quant data shows PHAT's Net Cash Flow at $50.9 million in Q1 2026, -$5.2 million in Q4 2025, and -$14.4 million in Q3 2025.